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ABSTRACT 
Background and objectives 
Current estimates of the number of new cases of cervical cancer in South Africa suggest that 
there are about 5743 new cases and 3027 deaths from the disease per year.   It is still unclear 
or poorly defined why women present late.   
The purpose of this study was to determine the stages of cervical cancer that women present 
with at Chris Hani Baragwanath Academic Hospital and to identify factors associated with late 
presentation.  
 
Methods 
This was a prospective study conducted at all the gynecology units of the O& G department at 
CHBAH in Soweto, Gauteng Province over 12 months period between January and December 
2013.  
 
Results 
A total of 111 women were recruited into the study. Only 104 women were included in the 
study.  Two (2) women withdrew due to personal reasons. Three (3) women were excluded as 
their fully histology report could not be retrieved.  Two (2) women could not continue with the 
interview due to pain and discomfort. 
x 
 
The mean age of women was 50.2 years (SD±12.30) with an IQR   of 40.50-49.50. The mean 
ages for stage 1 were 42.22 (SD±10.34), 51.00 (SD±12.54) for stage 2, 51.60 (SD±12.34) for 
stage 3 and 47.10 (SD±13.35) for stage 4 [p-value of 0.16].  
The majority of women (67.31%) in our study are from a poor socio-economic environment 
with a combined family earning of less than three thousands rand.  
Abnormal vaginal bleeding was the commonest reason for consultation (48.54%).  43 women 
(41.75%) first discussed the problems with their family members for input and advice before 
consulting any healthcare facility. Almost 48% of women still do not know about Pap smear. 
 
Conclusion 
Women with late stages of cervical cancer are more likely to be older than 50 years, come from 
a low socio-economic background and more likely to have not completed high school. There is 
an increase in incidences of adeno-carcinoma presenting with stages 3 and 4 of the disease. 
Vaginal bleeding remain the commonest symptom and probably a red flag for cervical cancer 
in post-menopausal women. However, many women delay seeking healthcare in our public 
health facility even after identifying the signs and symptoms suggestive of cervical cancer.  We 
speculate discussing with family members and seeking opinion could be the result for delayed 
consultation. There is a need to continued education on cervical cancer warning signs and 
screening programs.      
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CHAPTER 1:  
 
1.1 INTRODUCTION 
It is saddening that even in this era of advanced healthcare and technology, cervical cancer 
remains the second most common cancer among women worldwide and the commonest 
among black women in S.A.1- 6 
Ironically, cervical cancer is one of the few medical conditions with a precursor lesion which if 
detected early and treated, can result in a reduction in both incidence and mortality.1, 7 Most 
cases, approximately 80% occur in developing countries.4, 6 The morbidity is also higher in 
developing world where more than 50% of these women will succumb to their disease within 
the first year of diagnosis.1 In Western Europe, North America, and Japan the mortality is down 
to about 35%.15 There are many factors such as advanced presentation,2, 7, 8 co-morbid 
diseases, and lack of treatment centres7 which may be responsible for the poorer prognosis in 
developing countries.1, 6 Even in the developed world, such countries as Japan and Malaysia, 
most patients are still presenting at stages IIB, III-IV and a mere 26% present at stage I.9, 10  
In South Africa the cervical national screening programme has been ongoing for more than 10 
years (implemented 2003) but we would expect that there may be an increase in new cases 
diagnosed at early stages of the disease.1 The HPV Vaccine school program for children 9 to 12 
years has been implemented in 2014 and it is hoped that in the next decade we will start 
witnessing a decline in cervical cancer caused by this virus. There are no national statistics for 
Cancer of the cervix since 2004 as there hasn’t been a National Cancer Registry. However, the 
CMJAH Oncology unit managed/saw a total of 330 patients with cervical cancer in 2011. Of 
these, there were 0.09 % (n=3) of stage 1A, 6.60% (n=22) stage 1B, 3.0% (n=10) stage 2A, 
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36.9% (n=122) stage 2B, 1.8% (n=06) stage 3A, 44.5% (n=147) stage 3B, 4.8% (n=16) stage 4A, 
and 1.5% (n=05) stage 4B (information obtained by author from hospital records)  There is a 
dearth of knowledge on the specific stages of cervical cancer and the reasons for late 
presentation in South Africa.1 
 
1.2. HYPOTHESIS 
We theorise that although the reasons for late presentation could be multifactorial, in our 
setting the largest contributors are level of education, poor socio-economic status, lack of 
information, poor access to healthcare system, and delays in healthcare referral systems once 
the diagnosis is made. Cervical cancer is an AIDS defining condition and it occurs earlier in 
women who are HIV positive. 
  
1.3. PROBLEM STATEMENT 
Current estimates of the number of new cases of cancer of the cervix in South Africa suggest 
that there are about 5743 new cases and 3027 deaths from the disease per year.11   It is not 
known whether the stage at which women present has been different since the introduction 
of the national screening program in South Africa. Of all the provinces in South Africa, Gauteng 
is one of the provinces where screening may have reached 35-40% coverage (personal 
communication) but still experience problems with late presentation. Furthermore late 
presentation may be one of the reasons for high mortality in both developed and developing 
world.  It is still unclear or poorly understood why women present late.1 
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The purpose of this study is to define the stages at which women present and find reasons why 
women in South Africa present at late stages of the disease. One of the goals of cancer 
management is prevention and if prevention fails, then it is hoped that women will present with 
early stage disease. 
 
1.4. LITERATURE REVIEW 
1.4.1 Introduction 
The relationship between cervical cancer and Human Papillomavirus (HPV) as the main 
causative factor has been well established and high incidences of cervical cancer are 
associated with persistent infection with this virus.2, 3, 8, 12 We have illustrated, in the form of a 
flow diagram on figure 1.1 below, the factors that may influence morbidity and mortality.  
 
Figure 1.1: Factors influencing the morbidity & mortality of HPV associated cervical cancer  
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1.4.2 Incidence and mortality 
Cervical cancer had an estimated 530 000 new cases in 2008 globally.1, 11, 13, 14, 15 Developing 
countries experience the greatest   burden at more than 85% of the global cases. In these 
regions, it accounts for 13% of all female cancers1, 4, 15 and the highest incidence rates are 
observed in Sub-Saharan Africa, Melanesia, Latin America and the Caribbean, South Central 
Asia and South East Asia.4, 15 
In South Africa, it is estimated that there are 16.84 million women over the age of 15 years 
who are therefore at risk of cervical cancer (age above 15 years).10 Globocan in 2011 estimated 
the South African incidence of cervical cancer to be 23.3 - 32.4 /100 000. 15 
 
1.4.3 Natural history of cervical cancer 
The natural history of cervical cancer has been studied in the past 30-40 years.11 Persistent 
infection of the cervix with high-risk types of HPV is associated with progression to cervical 
dysplasia and cervical carcinoma.1, 2, 3, 5, 8, 13, 20 It is clear that the major aetiological agents of 
cervical carcinoma are the oncogenic subtypes of the HPV  Recent geographic studies using 
sensitive polymerase chain reaction (PCR) DNA testing methods to detect a wide spectrum of 
high risk oncogenic HPV types including 16, 18, 31, 39, 45, 52, and 35 have generally observed 
HPV prevalence to correlate with the population risks of cervical cancer.2, 4, 5, 7, 8, 11, 13, 18 It is 
acknowledged that there are other co-factors such as high parity, tobacco smoking and use of 
oral contraceptives that probably modify the risks in women infected with HPV.2, 3, 4, 5, 8, 20 Risk 
factors known to be associated with invasive cancer include:- 
 Low socio-economic class3, 5, 20 
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 Early age at first intercourse3, 20 
 Increased number of lifetime sexual partners3, 20 
 Smoking3, 4, 5, 7, 8, 18, 20 
 Hormonal contraceptive (although currently unclear).3, 4, 5, 20 
 
Cervical cancer progresses slowly over decades from pre-invasive cervical intra-epithelial 
neoplasia to invasive cancer 11, 18 a process that can take between 10 and 30 years; hence this 
allows us the opportunity to prevent its progression. 
During this post screening era, incidence rates of cervical carcinoma are now generally low in 
developed countries with age standardised rates less than 14.5 per 100 000.1, 4, 14 This pattern 
is relatively recent, however,  before the introduction of screening programs in the 1960’s and 
1970’s, the incidence in most of Europe, North America, Australia and New Zealand was similar 
to developing countries today.1 There is substantial decline in cervical cancer incidence and 
mortality, most clearly observed in parts of ( Western Europe and Australia) countries where 
there are well developed screening programs.1, 3 Declines are also evident in some developing 
countries particularly striking in China, where estimated age specific incident ratio (ASIR) in 
2002 was 6.8 compared with 7.8 in 1985.5 
 
1.4.4 The impact of HIV infection on cervical cancer 
It has been well known that HIV infection increases the risk of developing certain cancers and 
Kaposi sarcoma, Non-Hodgkin lymphoma and Cervical cancer have been classified as AIDS 
defining disease since 1993.3 Women infected with HIV have an increased risk of being 
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infected with HPV. Cervical cancer present 10 years earlier in HIV positive women and HIV 
positive women are considered to be at higher risk for cervical cancer.1, 3, 5, 7, 11 
 
1.4.5 Presenting symptoms 
The most common presenting symptom of cervical cancer is abnormal vaginal bleeding or 
discharge.5, 6, 18, 19, 20 Abnormal bleeding may take the form of post-coital spotting, inter-
menstrual bleeding, menorrhagia, or menopausal bleeding.5, 6, 19 
Sciatic pain or back pain associated with urinary tract infection, urinary obstruction, (and 
associated finding of hydronephrosis) may be the symptoms in advanced stages of the disease 
or with tumour necrosis of the tumour on the pelvic wall.6, 18, 19             
 
1.4.6 Staging of cervical cancer 
The Féderation Internationale de Gynécologie et d’Obstétrique (FIGO) system of classification 
(Appendix E) is based on clinical examination essentially of the anatomical extent of disease for 
all cancers except cervical cancer. The American Joint Committee on cancer (AJCC) staging is 
based on the premise that cancers of the same anatomic site and histology share similar 
patterns of growth and similar outcome6, 16. It is important to estimate the extent of the 
disease not only for prognostic purposes but also for treatment planning.5, 16, 17, 18, and 19.   
 
1.4.7 Commonest Clinical stages at presentation 
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In a program aimed at reducing by half the proportion of patients who present with advanced 
stage disease of breast cancer and cervical cancer over a 4 year period (a pilot study of clinical 
down-staging in Sarawak, Malaysia), it was shown that 70% of cervical cancer were diagnosed 
as stages III and IV for year 1993.1, 10 Delay in diagnosing the disease in Malaysia is common 
due to factors such as frequent reliance on unorthodox medical remedies at initial 
presentation.9, 10 
In other studies done on admitted patients at Penang hospital in 1995, 60% were in stages III-
IV.9  The study done in Kuala Lumpur found that 80% of patients with cervical cancer presented 
at stages IIB-IV 9 and in Sarawak, the proportion of patients with carcinoma of the cervix who 
presented with stages I and IIA was only 26.3%. The most common stage at presentation being 
stages III (36.2%).9 There is a consensus in all these studies that the commonest stages at 
presentation is FIGO IIB and above. 
 
1.4.8 Commonest reasons for presenting at late stages of the disease 
Snyman et al,  on their study of reasons why unscreened patients with cervical cancer present 
with advanced stage disease in Kalafong found that the lack of a cervical cancer screening 
programme, suboptimal management of symptomatic patients,  low levels of literacy and 
knowledge about cervical cancer and screening are compounding the plight of these 
patients.21 
Delay in diagnosing in Malaysia was found to be common due to factors such as frequent 
reliance on unorthodox medical remedies at initial presentation.9 
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Anorlu R.I et al found that in Lagos, patients' delay in seeking healthcare and healthcare 
providers' delay in referring patients to a tertiary hospital contributed to the late 
presentation.24 
In Zimbabwe, a study done at the Department of Radiology found that late stage tumour at 
presentation was significantly associated with poorly differentiated tumour histology and no 
history of prior cervical cancer screening. The odds of presenting with late stage disease in 
women with a poorly differentiated tumour were 12.97 (95% CI 2.03-82.55; p = 0.007), whilst 
the odds of late stage presentation in the absence of a history of screening were 11.13 (95% CI 
1.33 to 93.21; p = .026).23 
 
1.4.9 Mortality related to stage of presentation 
The mortality and morbidity of disease is related to stage at presentation and other factors 
such as age, smoking, co-morbid diseases, invasion of lymphatic and blood vessels, histological 
types and incomplete excision. 5,6,19 Older patients have a lower survival for any given stage.6 
Table 1.1 below shows that there is marked difference in 5 year survival rate between early 
stages of cervical cancer and late stages25. 
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Table 1.1 Association between FIGO early & late stages of cervical cancer & their 5 year survival) 
(Source: Benedet J, Odicino F, Maisonneuve P, et al. Carcinoma of the Cervix Uteri: Annual report 
 on the results of treatment in Gynaecologic Cancer. J Epidemiol Biostat 2001) 
 
Patients with stage IVB cervical carcinoma are considered candidates for palliative radiation 
therapy because cure is not attainable.6 In stage IA1 disease, the risk of residual disease is as 
high as 33% if margins are positive after surgery (zonisation).16 Overall 5 year survival by FIGO 
stages (Annexure E) is 94.6% in stage IA1 and 22.0% in stage IVB. 
 
1.4.10 Management Principles 
A). Prevention 
i). Primary Prevention 
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Prophylactic HPV vaccines against certain oncogenic strains are now available and represent 
an important advance in the fight against cervical cancer as a primary preventive strategy.8, 12, 
13 Currently there are two registered prophylactic vaccines for HPV vaccination; Cervarix 
(GlaxoSmithKline) protects against HPV types 16 and18 and Gardasil (Merck), which protects 
against HPV 6, 11, 16 and 18.1, 8, 12, 13 However generations of women will not be eligible or will 
not be able to  access these vaccines and they will require secondary prevention. 
Other important factors in preventing cervical cancer include the reduction of smoking (both 
active and passive), the use of condoms and male circumcision.8 
 
ii). Secondary Prevention 
Secondary prevention is aimed at screening of the general population to identify and treat 
women with cervical cancer precursors.5, 8, 22 Basic screening can lead to down staging of 
cervical cancer. The South African National policy on cervical screening allows for three smears 
in a woman’s lifetime taken at 10 year intervals from 30 years of age. The deficiencies of the 
Pap smear are that it has a lower than expected sensitivity of only 54%.3, 7 It also has a 
deficiency of inadequate sample or non-representative tests although this is improved when 
liquid based cytology is used. The obstacles to an efficient national population-based screening 
programme are lack of capacity, lack of treating facilities and lack of knowledge in the patient 
population. The HIV pandemic has also placed a huge burden on screening because the 
prevalence of precancerous lesions in HIV positive women is between 50 and 70%.3, 7 
 
B). Treatment  
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Treatment of cervical cancer precursors prevents cervical cancer.1, 5 Treatment of early stages 
of cervical cancer is associated with reduced morbidity and is cheaper.  Treatment has to be 
individualised, but the following are some of the treatment options:  Stage 1a1 may be treated 
with a cone biopsy and may therefore be fertility sparing. 1, 5 Clear margins and a negative 
endocervical curettage are however mandatory. In our institution, older patients or patients 
who have completed their family are treated with a hysterectomy (abdominal or vaginal). 
Stages 1a2, 1b and some of the 2a tumours may be treated with Radical Hysterectomy with 
bilateral pelvic lymphadenectomy, clear margins and negative lymph nodes are mandatory 20, 
27.  If the lymph nodes are invaded by tumour, post-operative chemo-radiation should be 
given.27 Stage 2b and stage 2a not amenable to surgery, or more advanced lesions are treated 
with a combination of chemotherapy and radiotherapy.5, 6, 19, 20, 27 
Earlier stage at diagnosis is associated with fewer complications, low cost as well as reduced 
morbidity.5 
 
Concurrent Chemotherapy and Radiation 
The main agents that have been used are 5-FU and cis-platinum, and both are also radiation 
sensitizers.5, 6, 19 Concurrent chemotherapy offers several theoretical advantages over the neo-
adjuvant strategy.5, 6, 18, 19 These include no delay in the start of definitive radiation and no 
prolongation of overall treatment time (thus minimizing the theoretical risk of accelerated 
oncogenic proliferation during the antineoplastic course).6    
Pelvic radiation dose for stage 2B is 50 Gy in 25 daily fractions, 40 Gy for stage 3b and palliative 
radiation dose of 20 Gy in two monthly fractions for stage 4 tumours. 27 
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1.5.  GENERAL OBJECTIVES OF THE STUDY 
To determine the stages of cervical cancer that women present with at Chris Hani 
Baragwanath Academic Hospital (CHBAH) and to identify factors associated with late 
presentation between January 2013 and December 2013.  
 
1.6.  SPECIFIC OBJECTIVES OF THE STUDY 
1. To determine the stages of cervical cancer that women present with at CHBAH. 
2. To describe the socio-demographic factors    
3. To identify the presenting symptoms. 
4. To compare the socio-demographic factors, symptoms, co-morbid disease and 
laboratory parameters of the women with different stages of disease at presentation 
5. To investigate whether women are able to recollect when their symptoms first 
commenced. 
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CHAPTER 2: SUBJECTS AND METHODS 
 
2.1 STUDY SETTING 
The study was conducted at the CHBAH. This is a secondary-tertiary hospital which serves the 
population of Soweto and Southern Gauteng. Chris Hani Baragwanath Academic Hospital 
(CHBAH) is situated to the South West of Johannesburg, on the southern border of Soweto. It 
services about 2 million people and it is a referral centre for 7 Community health centres, in 
the surrounding areas of Soweto, Orange Farm and Lenasia and receives referrals from 56 
clinics as well as district hospital. (South Rand hospital).  
CHBAH also take referrals from hospitals outside of the Johannesburg Health District and from 
outside of Gauteng province.  
The women with cervical cancer were admitted by any unit of the gynaecology wards and all 
worked up for presentation at the combined oncology meeting at the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) where decision regarding treatment modalities was 
made. 
 
2.2 STUDY POPULATION 
All women have a biopsy to confirm the malignancy and have a complete examination, Chest 
X-ray, Liver Functions Test (if necessary), Urea &Electrolytes, Full Blood Count, Cystoscopy (if 
necessary) and an Abdominal Ultrasound.  A Computed Tomography (CT) or Magnetic 
Resonance Imaging (MRI) is performed on selected cases. 
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All patients diagnosed histologically as cancer of the cervix at the Gynaecology Department at 
CHBAH were requested to participate in the study after they had been diagnosed and staged. 
The staging is performed by the senior consultant in the unit and re-examined by another 
consultant for agreement. The gynaecology department sees approximately 200 cases of 
cervical cancer per year as either emergencies at admission ward or cold cases seen at follow 
up clinic. 
  
2.3 SAMPLE SIZE 
The study was conducted over a period of twelve (12) months. We had a convenience sample 
of 111 women due to researcher unavailability at the hospital as a result of scheduled rotation 
at other hospitals within the Witwatersrand circuit as well as outreach at regional hospitals.  
The main objective of the study was to describe the stages at presentation and there was 
therefore no sample calculation done. 
Exclusion criteria: 
o All patients with histologically proven pre-malignant disease. 
o Women with late stage who cannot consent because of advanced disease or any other 
reason. 
o Women with recurrent disease. 
o Women diagnosed prior to the onset of the study. 
The patients were not re-examined by the researcher. 
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Recruitment: 
All units were asked to refer any woman with cervical cancer diagnosed on histology to the 
researcher. The researcher then explained the study to the patients. Women were invited to 
voluntarily take part in the study and permission was requested from them or the next of kin.  
All women who agreed to form part of the study were given the information pamphlet and 
they signed consent. 
 
2.4 STUDY DESIGN 
This was a prospective, descriptive study for period January 2013 to December 2013, using a 
record review and, an interview. After the administered interview women were asked when 
they thought the problem started and this was recorded on tape and at later stage transcribed 
by the researcher. 
 
2.5 DATA COLLECTION 
A questionnaire (Appendix A) was used to interview women.  Data was collected from 
patients’ file (part A), patients’ interview in the form of close-ended short questions (part B) 
and at the end, two open-ended questions was asked (part C) and these were recorded and 
transcribed by the researcher. The information on the data collection sheet included the 
demographic data, health seeking behaviour, sexual and contraceptive history, social 
behaviour, cervical cancer screening, HIV status, as well as presenting symptoms. The open 
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ended questions were recorded on Dictaphone and patients were made aware of such prior to 
the interview. 
During each visit to the gynaecology wards (ward 60 and ward 61) the admission book was 
checked for newly admitted patients. The record of their admission status, that is, whether 
they are readmissions or new admissions was checked before the interview took place. Only 
newly diagnosed patients were recruited. Women who fit the inclusion criteria were then 
invited to be part of the study and they gave consent in writing. Data was collected as 
reflected on the data collection sheet. Demographic details not documented on the patient’s 
files were confirmed with the patients. Any results, including histology, were confirmed from 
the records and if not available were checked on the National Health Laboratory Services 
(NHLS) database. This included the checking of a previous Pap smear.  
The stages at which women presented was recorded as documented on the file and this was 
confirmed to have been staged by the senior consultant in the unit. The patients were asked 
about their HIV status, CD 4 level if positive, and whether or not they were taking ARVs as well 
as the duration in both months and years of taking them. The results of tests such as 
Haemoglobin, Rapid Plasma Reagan, Renal Function tests, Liver Function tests and Urine 
Cytology were checked on both patients file and NHLS system if not present in the file.  
The hospital file was used to check if weight assessments were done on admission, record of 
ultrasound scan and chest radiography investigations. The smoking history included the type 
of nicotine ever used (snuff and cigarette), duration, and whether they are still using or not.  
Contraceptive history was about whether they ever used any contraceptive without 
considering sequential use. This history included the method, regularity of use, duration and 
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whether still using or not per each method of contraception. In this category, natural method 
and other less reliable methods were not included. 
The main provider was considered to a person who is mainly responsible for payment of major 
household bills including food, schooling, lights, water and municipal rates. Patients were 
asked about total family income which included monies from main provider and any other 
monies from any other source or person who contributes at regular bases.  
Accessibility to a healthcare facility was done using method of transport to access this service. 
A short trip was considered to be the one where one taxi trip is required to reach the facility or 
a drive of less than 60 minutes if utilising own transport.  A long trip was considered to be the 
one where more than one taxis or a connecting taxi is used to arrive at healthcare facility or a 
drive of more than 60 minutes in own transport (at normal traffic flow period). If patients 
could walk to clinic, this was noted as a different category (walking distance). 
When patients were asked if they know about Pap smear, it was further described to them 
“that this is a test used to check for cancer of the mouth of the womb in women”. The NHLS 
system was used to confirm if Pap smear was ever done before the current diagnosis and the 
results thereof. Patients were asked to elaborate what healthcare workers did after telling 
them results in an attempt to find out if colposcopy, colposcopy and LLETZ or biopsy was done. 
The number of lifetime partners was asked circumstantially by asking first the age of first 
sexual encounter and whether this was at school, whether this is the person they married or 
stayed with, whether they were still together in tertiary (if tertiary advanced), if they are still 
alive, if they dated again after partners demise, if there was a point where they had more than 
one sexual partner or due to any reason had sexual interactions whilst in a relationship. From 
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this history, a total number of life partners were calculated. This was due to the fact that 
elderly patients were hesitant to volunteer a total of lifetime sexual partners.  
Patients were asked in an open-ended question what made them consult relating to the 
current admission. This answer was then categorised into bleeding, pain, abnormal discharge, 
screening etc. They were also asked to explain what they did first after identifying the 
symptoms and this was also categorised as well into groups of those women who consulted 
family, those who consulted healthcare worker (further sub-categorised) as well as alternative 
medicine and spiritual healers. 
 
2.6 DATA ANALYSIS 
Data collected was uploaded onto the excel spread sheet and then transferred to a STATA 10.1 
(StataCorp, Texas, US) for statistical analysis. Categorical variables were described using 
frequencies and percentages and continuous variables were described using means (with 
standard deviation) and medians with intra quartile ranges (IQR). We only reported the mean 
if the mean and median were the same. Comparison of categorical variables was made using 
the Chi2 or the Fisher test, and continuous variables were compared using the T-test or an 
Anova test where there was a difference of two (2) means. A p<0.05 was taken as statistical 
significance.  
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2.7. ETHICAL ISSUES 
Patient confidentiality was maintained throughout. No personal details were recorded in the 
data sheet and each patient was allocated a study number. Informed consent was signed by 
each patient with an opt-out option (Appendix C).  
Ethical clearance was obtained from the Human Research Ethics Committee (M121011) for the 
University of the Witwatersrand (Appendix D) and from the office of the Chief Executive 
Officer of the Chris Hani Baragwanath Academic Hospital (Appendix F).  
 
2.8. TOOLS USED 
1. A questionnaire: In English but questions were translated to other languages 
where needed. ( the researcher is able to speak eight of the eleven official languages) 
2. A voice recorder/Dictaphone(Sony IC Recorder ICD-UX523F)  : For the open-ended 
questions  
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CHAPTER 3: RESULTS 
 
3.1 Introduction 
In this chapter I will start by describing the main findings in this study, that is, the proportion of 
women presenting with different stages of cervical cancer. I will then divide the results into 
sections; demographics, socio- economic factors, education, contraception, clinical features, 
co-morbid diseases, sexual history and histology. Variables that significantly related to the 
stage of disease were identified. I will compare the differences of each variable with the stage 
of presentation. Finally I will describe the women’s explanation of when they thought the 
disease started and other aspects of health seeking behaviour. 
 
3.2 Results 
There were 111 women recruited into the study out of the total 265 (including patients who 
do not fit into the selection criteria). Two (2) women withdrew from the study during the 
interview process for personal reasons. Three (3) women were excluded due to missing 
histology reports that could not be traced.  Two (2) women were excluded as they could not 
proceed with the interview due to pain and discomfort during the interview. Only 104 patients 
were included in the study. The stages at which these women presented are shown in Table 
3.1.  
 
 
21 
 
Table 3.1 Description of the proportion of women presenting with different stages of cervical 
carcinoma at CHBAH 
Cervical Cancer Stage       Frequency Percentage (%) 
Stage1a 3 2.88 
Stage 1b 6 5.77 
Stage 2a 5 4.81 
Stage 2b 18 17.31 
Stage 3a 6         5.77        
Stage 3b 56 53.85 
Stage 4a 7 6.73 
Stage 4b 3 2.88 
Total 104 100.00 
 
 
Demographics: 
The mean age was 50.20 years (SD±12.3) and the median was 49 years with an IQR of 40.50-
49.50. Their ages ranged between 28 and 81 years. The mean times that a woman was 
pregnant was 3.85 (SD±2.07) with a range of 1 to 11. The pregnancies reached term in 80.39% 
and 17.65% had a preterm delivery. The mean interval between children (child spacing) was 
4.47 years (SD±2.50). 
Most women (n=87 [83.65%]) were non- smokers and 15(14.42%) had smoked or were still 
smoking. Smoking history was unknown in 2 (1.93%). 
A history of ever using snuff was present in 28 (27.18%) women, one woman did not answer 
the question. Table 3.2 below compares the demographics per staging of cervical cancer. 
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There were (n=57) 54.81% of women who were main providers within their households and 
(n=47) 45.19% were not main providers. 
There were (n=18) 17.31% of women who had a combined family income of less than R1000 
per month, (n=52) 50.00% had a combined income between R1000-R2999, (n=18) 17.31% had 
family income between R3000-R4999 and (n=16)15.38% had a total family income of more 
than R5000. 
Fifty one women (49.04%) attended school but did not complete matric, (n=17) 16.35% had no 
formal education, (n=25) 24.04% attended completed primary school but without secondary 
education, (n=7) 6.73% had secondary education post matric, (n=4) 3.85% had a tertiary 
qualification either at university, college or FET (Further Education and Training) institution. 
Table 3.2 below compares the demographics per staging of cervical cancer. There were no 
statistically significant differences across categories. 
 
CHBAH serves the Soweto Township and surrounding areas. There were 86.41% of women 
who stayed in the townships and 6.80% from the Johannesburg suburbs.  There were an equal 
percentage of women from the city (excluding suburbs) and informal settlement at 2.91% 
each. One patient (0.97%) was from the rural/farm area. Figure 3.1 below shows the 
distribution of patients per residential locations. (This is excluding patients from outside 
Soweto townships and outside of Gauteng province who are either referred or “immigrate” for 
healthcare reasons. 
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Table 3.2  The demographics of women per stages of cervical cancer 
Cervical Cancer 
Stages 
Stage 1 
n=9 (8.65%) 
Stage 2 
n=23 (22.12%) 
Stage 3 
n=62(59.62% 
Stage 4 
n=10 (9.61%) 
p-value 
Age: Mean= 
50.2 years 
(SD±12.3) 
42.22 
(SD±10.34) 
51.00 
(SD±12.54) 
51.60 
(SD±12.34) 
47.10 
(SD±13.35) 
p=0.16 
(anova)  
Pregnancy History 
Number of 
pregnancies 
Mean= 3.85 
(SD±2.07) 
 
2.89 
(SD±1.54) 
3.30  
(SD±1.69) 
4.18 
(SD±1.99) 
4.00 
(SD±3.33) 
p=016 
(anova) 
Gestation at delivery**  
Term 5 (55.56%) 21 (91.30%) 47 (81.03%) 9 (90.00%) p=0.12 FE* 
Preterm 4 (44.44%) 2 (8.70%) 11 (18.97%) 1 (10.00%)  
Pregnancy outcome*** 
Live birth 6 (66.67%) 19 (82.61%) 49 (80.33%) 9 (90%) p=0.05 FE* 
IUFD 1(11.11%) 2 (8.70%) 0  1 (10.00) 
Miscarriages 2 (22.22%) 2 (8.70%) 12 (19.67%) 0 
Cigarette smoke (ever smoked)**** 
 
Yes=15 2 (22.22%) 5 (21.74%) 5 (8.33%) 3 (30%) p=0.09 
No=87 7 (77.78%) 18 (78.26%) 55 (91.67%) 7 (70%) 
Snuff use (ever used) 
Yes  0 5 (21.74%) 22 (35.48%) 1 (10.00%) p=0.08 
FE* 
No 8 (100%) 18 (78.26%) 40 (64.52%) 9 (90.00%) 
Family income in SA Rands 
<1000 
n=18 (17.31) 
2 (22.22%) 2 (8.70%) 12 (19.35%) 2 (20.00%) p=0.44 FE* 
1000-2999 
n=52(50.00%) 
2 (22.22%) 12 (52.17) 34(54.84%) 4 (40.00%) 
3000-4999 n=18 
(17.31%) 
3 (33.33%) 5 (21.74%) 9 (14.52%) 1 (10.00%) 
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>5000 
n=16 (15.38%) 
2 (22.22%) 4 (17.39%) 7 (11.29%) 3 (20.00%) 
Education 
No school n= 17 
(16.35%) 
1 (11.11%) 0 (0.00%) 13 (20.97%) 3 (30%) p=0.07 
Primary school only 
n= 25 (24.04%) 
1 (11.11%) 7 (30.43%) 16 (25.81%) 1 (10.00%) 
Secondary (no 
matric) n=51 
(49.04%) 
6 (66.67%) 13 (56.52%) 28 (45.16%) 4 (40.00%) 
Matric n=7 (6.73%) 1 (11.11%) 3 (13.04%) 3 (4.84%) 0  
Tertiary n= 4 (3.85%) 0 0 2 (3.23%) 2 (20.00%) 
*FE= Fishers Exact. ** = 2 women were unsure and 2 were nulliparous  ***= 1 woman did not answer 
****= 2 women declined to comment.  
 
 
 
Figure 3.1 Geographical distribution in Soweto and surrounding areas of 88 of the 104 women 
included in the study. (Map downloaded from: www.sahistory.org.za/soweto-map-webgif) 
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Contraception: 
There were 32.69% (n=36) of women had ever used combined hormonal oral contraceptive 
and the mean age for starting was 23.11 years (SD±7.52). Ever use of Medroxyprogesterone 
acetate injectable contraceptive was used in 50.49% (n =52) women, with a mean age at first 
use of 22.40 years (SD±10.73). The mean duration of use was 5.16 years (SD± 6.29). 
Norethisterone enantate was used in 17 (16.35%) women, with the mean age at first use of 
21.83 years (SD± 9.68). The mean duration of Norethisterone enantate use was 5.28 (SD±4.02). 
The use of progesterone only contraceptives pill was 3.88% with a mean age at first use of 28 
years (SD± 4.08).  The mean duration use was a mean of 5.75 years (SD±7.50). There were 
(n=7) 6.80% of women who used intrauterine contraceptive devices (IUCDs) with the mean age 
at use of 23.12 years (SD±11.83). Women who used IUCDs used it for an average of 4.57 years 
(SD±6.85). There were (n= 41) 39.42% who said that they used condoms as barrier 
contraceptives. The mean age of first use of condom was 27.36 years (SD±14.71). The 
proportion of women who used condoms consistently were (n=15) 36.59% whereas (n=26) 
63.41% admitted to interrupted use. Women who used condoms used them for a mean 
duration of 5.75 years (SD±4.50). The use of contraceptives per cervical cancer stage is 
described on table 3. There were no statistically significant differences between the stages of 
cervical cancer and contraceptive type. 
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Table 3.3 A comparison of ever use of contraception (and type) with different stages of cervical 
cancer. 
Contraceptive 
(inclusive) 
Stage 1 
n=9  
Stage 2 
n=23  
Stage 3 
n=62  
Stage 4 
n=10  
p-value 
Yes (ever used) 0 5 (21.74%) 22 (35.48%) 1 (10.00%) p=0.08 
FE* 
no 8 (100%) 18 (78.26%) 40 (64.52%) 9 (90.00%) 
COC n=34 3(33.33% 8 (34.78%) 20 (32.26%) 3 (30.00%) p=1 FE* 
POP n=4 1 (11.11%) 1 (4.55%) 2 (3.23%) 0 P=0.41 FE* 
IUCD  n=7 1 (11.11%) 2 (9.09%) 4 (6.45%) 0  P= 0.66 
Condom n=41 5 (55.56%) 10 (43.48%) 21 (33.87%) 5 (50.00% p=0.47 
DMPA n=52 
(50.49%) 
6 (66.67%) 12 (52.17%) 30 (49.18%) 4 (40.00%) p=0.73 
Norethisterone 
enantate 
2 (22.22%) 3 (13.04%) 9 (14.52%) 3 (30.00%) p=0.52 
Ever used 
hormonal 
contraception 
72 (69.23%) 
8 (88.89%) 15 (65.22%) 41 (66.13%) 8 (80.00%) p=0.52 
*FE= Fischer Exact. (The total number of contraceptive use per stage of disease add beyond 
total number on specific stage of disease due to some women having used multiple methods). 
 
Clinical features: 
The mean haemoglobin level on these women on admission was 10.2g/dl (SD± 2.8). The 
haemoglobin ranged between 3.3g/dl and 16.6g/dl. The median haemoglobin was 10.5, (IQR= 
8.15g/dl-12.35g/dl).  The table below compares the mean haemoglobin (g/dl) on admission 
per cervical cancer stage. 
Of the 104 women included in the study, only 92 women were weighed and their mean weight 
was 67.5kgs (SD± 18.5). The weight ranged between 32kgs and 120kgs.  Six (6) women were 
not weighed because they were very ill on admission and no reasons documented for the 
other six (6) who were not weighed. 
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There were only 6 women who were tested for syphilis on admission using the Rapid Plasma 
Reagent (RPR) or Treponema Pallidum Hem-Agglutinin (TPHA) test.  There were (n=1)16.6% of 
those who were tested positive.  
The renal function tests were done on 102 women on admission. The mean urea level was 5.7 
mmol/L (SD±8.0). [Normal ranges according to the National Health Laboratory services (NHLS) 
are 2.1 to 7.1]. The range was 1.70 to 58.00.  The mean creatinine was 119.4 umol/L 
(SD±227.8). The serum creatinine ranges were 36 umol/L and 1542 umol/L. (normal ranges 49-
90). Liver function tests were only done on 28 women. Over (n=26) 92.9% of them had normal 
findings and (n=2) 7.1% had deranged liver function tests. Urine cytology tests were done on 2 
women whom bladder involvement was clinically suspected. One of the two women (50%) 
whom urine cytology was done had bladder spread diagnosed on urine cytology. The 
differences between these clinical parameters are shown in the table below. 
 
Table 3.4 Comparison of clinical parameters during the admission period through the four 
clinical stages in women with cervical cancer 
Parameter Stage 1 
n=9 (8.65%) 
Stage 2 
n=23(22.11%) 
Stage 3 
n=62(59.62%) 
Stage 4 
n=10(9.62%) 
p-value 
Haemoglobin 
(g/dl) 
12.25 
(SD±2.36) 
11.25 (SD±2.98) 9.63 (SD±2.71) 9.85 (SD±2.16) P=0.01 
anova  
Weight (kg) 74.67 
(SD±20.30) 
71.69 (SD±16.56) 65.24 
(SD±19.02) 
62.29 
(SD±17.01) 
p=0.29 
Urea 
(mmol/l) 
3.58 
(SD±1.52) 
4.15 (SD±2.07) 6.69 (SD±10.02) 6.05 (SD±6.22) p=0.52 
anova 
 
Creatinine 
(umol/l) 
64 (SD±16. 66.65(SD±22.63) 141.62(271.88) 157.4 
(SD±285.23) 
 
p=0.46 
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Renal Ultrasound was performed on 100 women in whom 35 (35%) had either bilateral, 
unilateral hydronephrosis or hydro ureter.   
A chest radiograph was available in 97 women. Of these 88 (95.88%) had a normal study, 
2(2.06%) had lung metastases and 2(2.06%) had a pleural effusion or collapse. 
 
HIV: 
There were (n=52) 50.49% who were HIV negative and (n=51) 49.51% who were confirmed to 
be infected with the HIV. One woman refused to be tested.   The mean CD4 count for the 51 
women who were HIV positive was 403.80 (SD±223.30) [lowest CD4 was 24 and highest was 
1000].  
Sixteen women (32.65%) were not on Highly Active Anti-Retroviral (ARVs) whilst 33 (67.35%) 
were on treatment. The mean duration for HAART was 49.1 months (SD± 39.90). The minimum 
duration for HAART was one month and the maximum being 132 months.   
 
Table 3.5 A comparison of HIV, CD4, and HAART use in the different stages of cervical cancer 
HIV status & 
HAART use 
Stage 1 
n=9 (8.41%) 
Stage 2 
n=23 (21.50%)  
Stage 3 
n=61 (58.65%) 
Stage 4 
n=10 (9.35%) 
p-value 
Positive 6 (66.67%) 11(47.83%) 30 (49.18%) 4 (40.00%) p=0.73 
FE* 
Negative 3 (33.33%) 12 (52.17%) 31 (50.82%) 6 (60.00%) 
CD4 (if HIV 
positive 
512 
(SD±338.31) 
375 
(SD±160.55) 
364 (SD±199.35) 587.00(SD±29
4.55) 
p=0.19 
anova 
 use of HAART 
n=33 (67.35%) 
2 (40%) 7 (70%) 21 (70) 3 (75%) p=0.61 
FE* 
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No treatment  
n=16 (32.65%) 
3(60%) 3 (30%) 9 (30%) 1 (25%) 
Duration of 
HAART in 
months 
n=33 
60 
(SD±69.30) 
39.29 
(SD±27.81) 
48.42 
(SD±42.06) 
70 (SD±45.03) p=0.73 
anova 
*FE= Fischer Exact. There was one woman who had stage 3 of the disease who declined to test 
for HIV 
 
Sexual History: 
The mean age for coitarche was 17.81 years (SD± 3.33). The mean number of life partners was 
4.06 (SD±3.26). There were 29 women (27.88%) who said they had had a sexually transmitted 
infection (STIs), 72(69.90%) denied having had STIs and 3(1.94%) declined to comment. 
 
Table 3.6 The sexual lifestyle and STDs in women with cervical cancer at different stages of the 
disease 
Parameters Stage 1 
n=9 (8.65%) 
Stage 2 
n=23 (22.11%)  
Stage 3 
n=62 (59.62%) 
Stage 4 
n=10 (9.62%) 
p-value 
Sexual History 
Coitarche 18.22 (SD±0.83) 18.09 
(SD±2.83) 
17.45 (SD±2.85) 18.70 
(SD±6.83) 
p=0.66 
  
Life-time 
partners 
3.33 (SD±1.80) 3.91 (SD±3.03) 3.93 (SD±3.28) 5.8 (SD±4.42) p=0.34 anova 
 
History of STD 
no 7 (77.78) 15 (18.18) 44 (73.33%) 6 (60%) p=0.79 FE* 
yes 2 (22.22) 7 31.82%) 16 (26.67%) 4 (40%) 
*FE= Fishers Exact     
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Histology: 
Squamous cell carcinoma was the commonest histological type making up (n=91) 87.50% of 
the cancers. Adenocarcinoma accounted for (n= 7) 6.73% and (n=2) 1.92% were adenoid cystic 
carcinoma and serous carcinoma. Adenocarcinoma only occurred in patients with stage 3 and 
4 disease (Table 3.7). Histological grading was not reported on (n=19) 18.27 % on the histology 
report, (n=6) 5.77% were well differentiated, (n=65) 62.50 % were moderately differentiated, 
(n=13) 12.50 % were poorly differentiated and (n=1) 0.96 % were heterologous and 
categorised as other(s).  On all the four stages, the highest histological cell types were those of 
the squamous cell as shown on table 3.7 below.  
 
Table 3.7 The percentages of histological types of cervical cancer. (The histological type classified as 
“other” included adeno-cystic carcinoma and papillary serous carcinoma) 
Histological types Stage 1 
n=9 (8.65%) 
Stage 2 
n=23 (22.11%)  
Stage 3 
n=62 (59.62%) 
Stage 4 
n=10 (9.62%) 
p-value 
Squamous 8 (88.89%) 20(86.96) 55(88.71% 8 (80%) p=0.22 
FE* 
Adenocarcinoma 0 0 5 (8.0%) 2 (20%) 
Adeno-squamous  1 2 1 0 
Other 0 1 1 0 
*FE= Fischer Exact 
 
Health seeking behaviour: 
There were (n=74) 71.15% of women who stayed a walking distance from the clinics or 
healthcare facilities, (n=27) 25.96% needed to use a transport to access clinics or healthcare 
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facilities although the trip was perceived as short, (n=3) 2.88% of women used a transport for 
one long trip or two trips to access clinic or healthcare facility.  
A third (1/3) of the study population, (n=78) 75%, knew what a Pap smear was and (n=26) 25% 
did not know. However only (n=55) 52.88% had done Pap smear before. The mean time that 
the last Pap was performed was 61.2 months (SD±87.30). Of the 53 patients who had done Pap 
smear before the current diagnosis of malignancy, (n=16) 30.19% had a normal cytology, 
(n=28) 50.94% had an abnormal cytology. The abnormal cytology included LGSIL (n=2), HGSIL 
(n=21), ASCUS (n=3), and Invasive cancer (n=2).  The intervention after abnormal Pap smear 
was mostly punch biopsy with (n=11) 34.38%. Colposcopy & LLETZ was done in (n=10) 31.25% 
of women whereas colposcopy alone was done on (n=2) 6.25% of women with abnormal Pap 
smear. There was a (n=5) 15.3% of women who were uncertain as to what intervention was 
done and (n=4) 12.50% defaulted the follow up booking for intervention. 
The mean age for coitarche was 17.81 years (SD±3.33). The mean number of life partners was 
4.06 (SD±3.26). There were (n=29) 28% women who said that they had had a sexually 
transmitted infection (STIs), (n=72) 69.90% denied having had STIs and (n=2) 1.94% declined to 
comment. 
 
Table 3.8 The screening of women, knowledge about Pap smear and Pap smear results at least 
six months before admission  
Pap Smear Stage 1 
n=9 (8.65%) 
Stage 2 
n=23 (22.11%)  
Stage 3 
n=62 (59.62%) 
Stage 4 
n=10 (9.62%) 
p-value 
Do you know what a Pap smear is? 
No n=26 (25%) 1 (11.11%) 4(17.39%) 17 (27.42%) 4 (40.00%) p=0.42 FE* 
Yes n=78 (75%) 8 (88.89%) 19 (82.61%) 45 (72.58%) 6 (60.00%) 
32 
 
Have you done a Pap smear before the current? 
Yes  7 (77.78%) 12 (52.17%) 30 (48.39%) 6 (60%) P=0.41 FE* 
Last pap period 
(months)  
33.16 
(SD±30.66) 
88.08 
(SD±112.21) 
65.73 
(SD±89.49) 
13.17 
(SD±11.41) 
p=0.31 
 
Last pap results 
normal 3(42.86) 3 (25%) 9 (32.14%) 1 (16.67%) P=0.70 (FE* 
abnormal 3 (42.86%) 8 (66.67%) 12 (42.86%) 4 (66.67%) 
unknown 1 (14.29%) 1 (8.33%) 6 (21.43%) 0 
inconclusive 0 0 1 (3.57%) 1 (16.67%) 
*FE= Fishers Exact     
 
There was one patient who declined to comment on reasons for consulting. Of the 103 that 
commented, the commonest reason for health seeking/consultation during period when 
cervical cancer was diagnosed in these women was abnormal vaginal bleeding at (n=50) 
48.54% followed by bleeding and pain at (n=27) 26.21%. There were (n=12) 11.65% of women 
who consulted due to pain only and there was an equal percentage, (n=5) 4.85%, for those 
who visited health facility for screening as well as for vaginal discharge only. There were (n=2) 
1.94% of women who consulted due to non-specific symptoms and (n=2)1.94% who consulted 
due to vaginal discharge with pains. Reason for consultation per cervical cancer stage is shown 
on table 3.9 below. 
 
Table 3.9 A comparison of reasons for consultation with stages of cervical cancer at 
presentation of the 103 women. 
Reason for 
consultation 
Stage 1 
n=9 (8.65%) 
Stage 2 
n=23 (22.11%)  
Stage 3 
n=62 (59.62%) 
Stage 4 
n=10 (9.655%) 
 p-
value 
Screening (No 
symptoms) 
2 (22.22%) 1 (4.35%) 2 (3.28%) 0 5 p=0.26 
FE* 
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Bleeding only 6 (66.67%) 15 (65.22%) 26 (42.62%) 3(30.00%) 50 
Pain only 0 1 (4.35%) 8 (13.11%) 3 (30.00%) 12 
Discharge only 0 0 5 (8.20%) 0  5 
Bleeding and 
pain 
1 (11.11%) 6 (26.09%) 17 (27.87%) 3(30.00%)  27 
Discharge and 
pain 
0 0 1 (1.64%) 1(10.00%)  2 
Non specific 0 0 2 (3.28) 0  2 
TOTAL     103  
No answer 0 0 1 0 1  
*FE= Fishers Exact. (Bleeding includes post coital bleeding, intermestural bleedinga and post 
menopausal bleeding). One patient with stage 3 of the disease did not answer) 
 
Symptoms experienced before consultation: 
In the six months period before consultation, women reported to have had multiple 
symptoms.  
When asked about experiencing per vaginal discharge six months prior to the interview, (n=64) 
62.14% reported to have had it and (n=39) 37.86% denied having discharge. The discharge was 
reported to have been noticed for an average period of 6.74 months (SD±4.87). The discharge 
was described to be yellowish by (n=28) 43.75% of women, whitish by (n=20) 31.25% of 
women, brown by (n=14) 21.88% of women and red by (n=2) 3.13% of women. The discharge 
was also described as offensive by (n=59) 92.19% of women whereas (n=5) 7.81% reported it 
to be non-offensive. 
When asked about experiencing pain in the past six months prior to the interview, (n=84) 
81.55% reported to have experienced it and (n=19) 18.45% denied having had pain. The mean 
duration of painful stimuli was 7.94 months (SD±7.82). The pain was graded as mild by (n=9) 
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10.71% of women, moderate by (n=47) 55.95% and severe by (n=28) 33.33% of women.  There 
were (n=76) 90.48% who reported that the pain had not been improving since first experience 
and (n=8) 9.52% reported improvement. The highest pain scoring was seven (7 out of 10) at 
18.60% of total scores from 0 to 10. 
Abnormal vaginal bleeding (post coital, intermenstrual and postmenopausal) in the six months 
prior to the interview was experienced by (n=92) 89.32% and (n=11)10.68% had not had any 
bleeding. Dyspareunia in the six months prior to the interview, was present in (n=40) 39.22% 
of women and (n=1) 0.98% did not comment. The average duration of the dyspareunia on 
those who experience it was 9.58 months(SD±7.70) The dyspareunia was graded mild by 
women (n=8) 19.51%, moderate by (n=15) 36.59% of women and severe by (n=18) 43.90% of 
women.  
Weight loss was experienced by (n=18) 80.58%, these women noticed the weight loss on 
average 6.96 months (SD±6.56) months prior to the interview. Night sweats was experienced 
by (n=18) 17.48%. The mean duration for these night sweats was 7.88 months (SD±7.96). 
 
Attitudes, perception and knowledge about disease: 
When asked about the immediate action taken after noticing the symptoms (in an open 
ended-question on Section C of the questionnaire), (n=43) 41.75% of women indicated that 
their first action or response was to discuss with family or a family member, (n=29) 28.16% 
consulted the hospital or clinic first, (n=14) 13.59% consulted a private general practitioner, 
(n=12) 11.65% consulted a traditional healer or faith healer, (n=3) 2.91% decided to just 
observe the condition and (n=2) 1.94% did not answer. 
35 
 
There were (n=89) 86.41% women who consulted with a health worker for other health 
problems not related to cervical cancer in the past year. Of those, (n=43) 47.78% consulted at 
clinic or hospital, (n=16) 17.78% consulted for health care reasons at multiple sectors, (n=12) 
13.33% at the private general practitioner, (n=10) 11.11% at traditional healer, (n=7) 7.78% at 
faith healers, (n=2) 2.22% at alternative medical care givers such as acupuncturists.  
When asked if they perceive or thought the problems (presenting signs and symptoms) they 
had was a major problem, (n=50) 49.51% replied yes, (n=49) 47.57% did not see it as a major 
problem and (n=3) 2.91% declined to comment. There was one woman (0, 97%) who was not 
certain. 
Cancer was thought to have started when the first symptoms were experienced by (n=53) 
51.46% and (n=14) 13.59% thought the cancer started before the symptoms. There were 
(n=36) 34.95% of women who indicated that they did not think “they can know” when the 
cancer started. Women who reported to have been told about Pap smear before the current 
diagnosis were (n=49) 47.57%. Of these women, (n=41) 83.67% were told by healthcare 
workers, (n=5) 10.20% learned about Pap smear from their community, (n=2) 4.08% were told 
by a family member, (n=1) 2.04% learned about the test from the media.  There were (n=54) 
52.43% of women who denied ever been told about the Pap smear before.   
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CHAPTER 4: DISCUSSION 
 
4.1 Introduction 
In this section I will be discussing the findings of the study and the trends in comparisons with 
local/regional and internationally published similar studies per variable.  
 
4.2 Commonest presenting stages 
The commonest stages at presentation in our study is stage IIIB with 53.85% of cervical cancers 
followed by stage IIB with 17.31%. The overall comparison of early stages (IA to IIA) versus late 
stages (IIB to IVB) shows that 13.54% presents at early stages of the disease whereas 86.54% 
presented at late stages.  These findings are comparable with international studies done in 
Sarawak (Malaysia),9, 10  Penang hospital in 1995, 9 and Kuala Lumpur9 as well as local study 
done at Kalafong Hospital in Pretoria by Snyman et al 21 where the commonest stage was IIIB 
with 56.5%. These findings show an unchanged trend when compared with patients seen at 
Charlotte Maxeke Combined Gynaecology Oncology unit in 2011(n=330 where 86% of patients 
presented at late stages and 14% presented early (0.9% were stage IA, 6.6% stage IB, 3.0% 
stage IIA, 36.9% stage IIB, 1.8% IIIA, 44.5% IIIB, 4.8% stage IVA and 1.5% were stage IVB) 
(unpublished statistics).    It may be that this is the stage at which women become 
symptomatic, but this was not tested in this study. 
Most of the tumours, n= 65 (62.50%) in our study were moderately differentiated. There were 
only n=13 (12.50%) which were poorly differentiated tumours. This is contrary to a study in the 
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Southern African region (Zimbabwe) that found that late stage tumours were more likely to be 
poorly differentiated. The odds of presenting with late stage disease in women with a poorly 
differentiated tumour were 12.97 (95% CI 2.03 to 82.55; p = 0.007). 24  
 
 Most tumours (87.50%) were squamous cell carcinoma.  We found that in our study 
population, adenocarcinoma cervical cancers commonly presented at stage 3 and stage 4. 
Adenocarcinomas were only found in stage 3 (80.0%) [n= 5] and 4 (20.0%) [n= 2] cervical 
cancer.  It may be that the aggressive nature of these tumours results in advanced disease 
when detected. There has been a steady increase of adenocarcinoma in the world.  Currently 
adenocarcinoma constitute 15 to 20 percentage of cervical cancers. Our rate (6.70%) is lower 
than expected.  
 
4.3 Demographics 
4.3.1 Age 
In our study, the mean age for women with cervical cancer was 50.2 years. This is similar to 
publications in current literature that suggest the mean age for cervical cancer is 51.4 years. 
Moodley et al found that there was a difference in the mean age in HIV positive women and HIV 
negative women. Their mean age of HIV-positive patients was 15 years younger than that of the 
HIV-negative patients even though 40% of women are HIV positive.28  
4.3.2 Socio-economic status 
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The majority of women in our study are of low socio-economic class. More than 60% (67.31%) 
of these women’s households had a total combined monthly income of less than R3000.00. Even 
though these women were poor, many of them were still able to access health care at either 
public or private facilities (general practitioner). It has been found that low household income 
and lack of education play a major role in disease burden and favours progression of chronic 
diseases including cancer. Even though we did not look into the long term health seeking 
behaviour, in our study, socio-economic status did not appear to be associated with lack of 
consultation for health related problems. There was also no association between family income 
and late stage presentation. 
 
4.4 Factors associated with the commonest presenting stage of the study, stage 3. 
The commonest overall presenting stage on our study is stage 3(as discussed in section 4.2 
above) with 56 (53.85 %) women (Table 3.2). However, there were no statistical significance 
with any of the factors (demographic factors including contraceptive use etc.). 
The factors associated with stage 3 were the mean admission haemoglobin of 9.64 g/dl (SD 
±2.71) that was significantly lower (Table 3.4). The mean weight of 65.2kg (SD±19.02) and the 
use of combined oral contraceptives of 32.26% per total stage 3 women compared to other 
contraceptive methods did not differ from other stages (Table 3.3 and 3.4). These women 
(women who presented at stage 3) were also found to be of low educational status with n= 13 
(20.97%) who never attended school, n= 16 (25.81%) who only had primary school education 
and n= 28 (45.42%) who only had secondary education. The educational level between the 
different stages, however, did not differ significantly. 
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In SA screening coverage is between 20% and 40%. In our study, thirty (30) of the women who 
presented at stage 3 had a Pap smear done a mean 65.73 (SD±89.49) months before the 
interview and 9 (nine) had normal Pap smear what were the other results. This in comparison 
with the mean period since last Pap smear of 33.16 months (SD±30.66) for stage 1 and 88.08 
months (SD±112.21) for stage 2.  However six (6) of the stage 4 women did a Pap smear a mean 
13.17 months (SD±11.41) and 1 (one) had a normal Pap smear. Perhaps these women required 
a biopsy and not a Pap smear at time of visit. Stage 3 patients were also associated with a high 
proportion of women who have never done a cervical screening test, Pap smear. Seventeen (17) 
[27.42%] of stage 3 patients had never had a Pap smear. No significant relationship between 
screening and stage of disease were found (Table 3.8). 
Early age of coitarche is a risk factor for cervical cancer, but was not shown to be statistically 
different between the different stages in this study. The age at coitarche in our study is in 
keeping with that of the national South African average age, the Western African region as well 
that in European countries. 29, 30, 31 
The association between lifetime partners and cervical cancer is known.3, 20 There was a trend 
of increased number of lifetime partners in stage 4 as compared to stage 1 (5.8 life partners 
(SD±4.42) and 3.33 partners (SD±1.80) respectively) with an almost two fold increase in late 
stages. Although there was no statistically significant difference in lifetime partners through the 
stages, this trend was in keeping with current literature.3, 20 
Increase in parity is a risk factor for presenting in advanced stages of cervical cancer. This was a 
finding in our study although not statistically different across the stages. All these factors are in 
keeping with local and international studies on cervical cancer studies.  
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We found that the majority of patients’ cervical cancer could easily access public healthcare 
facility. With this behaviour, it is expected that many patients will present at precancerous 
lesions or operable stages of cervical cancer (1a to 2a).  There were 74 (71.15%) women who 
stayed a walking distance from the clinics, 27 (25.96%) women who required to travel to access 
the clinic although the trip was short and considered affordable. There were only 3 (2.88%) 
women in this study who stayed far from the health facility and had to travel a long distance or 
have two linked trips.    
 
4.5 Preferred area for first consultation after identifying symptoms related to cervical cancer 
Contrary to findings by Anorlu RI et al 24 who found that 60.71% of patients who presented in 
late stages of cervical cancer first went to consult at private hospitals, in our study 13.33% of 
patients consulted GP practices first, 11.11% consulted with traditional healers, 7.78% first 
consulted with faith healers and 2.2% opted to alternative medicine before consulting our 
public healthcare services. The inclusive percentage of patients who opted to seek medical 
consultation outside public healthcare facilities for symptoms related to cervical cancer was 
34.42%. There were 47.78% that consulted public clinics and hospitals first as well as 17.78% 
that had multiple facilities consultations before seeking healthcare at our institution. So it is 
interesting that all of the women consulted some practitioner. 
However, 43 women (41.75%) discussed the problems with their family members first for an 
opinion before consulting any healthcare facility. Although family support is associated with 
good coping, it has been associated with late stage presentation in a study done in Kenya by 
Were EO and Buziba NG26 on health seeking behaviour of cervical cancer patients. We speculate 
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that on our study, discussing with family could have delayed consultation.  We did not look at 
how long it took from the time of consultation with other providers to presentation at this 
hospital. 
 
4.6 Presenting Symptoms 
The commonest reason for consultation at either public healthcare facilities or other centres 
was abnormal vaginal bleeding only (48.54%). These findings were similar to a study done by 
Anorlu RI et al.24    A local study at Kalafong hospital in Pretoria also found that 74% of 
unscreened patients presented with bleeding either as menorrhagia, inter-menstrual bleeding 
or post-menopausal bleeding.21 The second commonest reason was a combination of both 
vaginal bleeding (including post coital bleeding) and abdominal pains (26.21%) followed by 
abdominal pain only 11.65%. Vaginal discharge (4.85%) and non-specific symptoms (1.94%) 
accounted for the rest of the reasons why women presented to a health care provider.  
 
4.7 Patients’ perception of onset of disease 
Although women were informed during the interview that cervical abnormal changes (pre-
malignant) that may result in cancerous lesions start way before the symptoms appear, 53 
(51.46%) women seem to think that cervical cancer started at the time the symptoms were 
observed. Only a tenth, 14 (13.59%) women seem to think that the cancer started before the 
symptoms. This raises the need for continued education on the importance of cervical cancer 
screening and prevention of progression of precancerous lesions to malignancy.  It also suggests 
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that one of the reasons this cancer presents late is because it remain silent or asymptomatic for 
a long time. 
 
4.8 Screening and knowledge about cervical cancer screening tests 
In this era of easy access to information from all types of media as well as in view of that the fact 
the majority of patients in our study had easy access to healthcare facilities, it is expected that 
almost everyone will know more about Pap smear and had at least done a test. However, in our 
study, n=26 (25%) of women still did not know what a Pap smear was.  This is considered 
alarmingly high and further raises question about how health education is dispensed. Only n= 
49 (47.57%) reports to have been told about Pap smear test before the diagnosing cytology. 
However, of these women, n= 41 (83.67%) were educated about the test by a healthcare worker.  
The 55 women who had done a Pap smear before the current diagnosis of malignancy did so a 
mean 61.2 months (5.1 years) prior to current diagnosis. This is below the 10 years period 
recommended in the national cervical cancer screening program. This finding suggest that there 
may be a need to review the screening interval in an attempt to reduce late stages presentation. 
 
4.9 Strengths of the Study 
This was a prospective study over a twelve month period. All the patients were seen and 
interviewed by the researcher himself. 
The researcher was able to directly communicate with the women in her preferred or spoken 
language without a need for a translator.  
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The data collection sheet had an open ended question at the end that aimed to affirm what was 
asked previously with close ended questions. 
 
4.10. Limitations of the Study 
The study population was a convenience sample and women were only interviewed on the days 
that the researcher was at CHBAH. 
We did not compare sub stages of cervical cancer in many variables due to a small study 
population. 
This was not a multi-centre study and was limited to one hospital, CHBAH. The findings could be 
biased due to a limited pool and lack of comparison and as such demographics could not be 
compared across the population. 
There could have been responder/recall bias when women were asked questions relating to 
sexual lifestyle such as coitarche and lifetime partners as many of our patients were older and 
showed hesitance in responding to these specific questions. 
There were women who could not be recruited into the study due to an administrative error 
(incomplete information) and some of the data could not be traced when the admission 
procedure was done manually due to hospital admission IT system failure. 
We did not look into the total number of people per household when asking about affordability 
and hence the total income per family may not directly translate to financial affordability. 
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CHAPTER 5: RECOMMENDATIONS AND IMPLICATIONS FOR PRACTICE AND 
RESEARCH  
Education for women regarding abnormal vaginal bleeding as “warning signs” of cervical 
pathology is very important and should be emphasised at all times when teaching about cervical 
screening and prevention.  
The questions that need to be answered are:  Are women consulting at these healthcare facilities 
even when they are at walking distance? Are women screened for cervical cancer utilising the 
current guidelines with every opportunity when they consult with a healthcare worker? And 
lastly, are women taking the opportunity to request a Pap smear test themselves? 
We did not explore more as to the women’s reasons for consulting the general practitioner, 
traditional healer, alternative medicine practitioners and faith healers first before consulting at 
a public healthcare facility. This requires further enquiry hence is an area for further research. 
The commonest reason for health seeking/consultation during period when cervical cancer was 
diagnosed in these women was abnormal per vaginal bleeding. We therefore recommend that 
women who have abnormal bleeding and a normal cervix should have a Pap smear even if they 
have had a screening Pap smear on the period covered by the national screening guidelines. 
They should not wait for the ten (10) years as suggested by the cervical cancer screening 
guidelines. 
A further study is needed to review the effectiveness of the current screening program’s 
interval. In our study 55.88% of women had done a Pap smear 6.1 years before the diagnosis of 
cervical cancer. We suggest that there may be a need to reduce the screening interval from 10 
years to 5 years. 
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CHAPTER 6: CONCLUSION 
Less than 30% (29.91%) of women presented with early stage disease and 70.10% presented 
with a stage 3b and above. The 5 year survival of women with late stages is 50.50%-22.00%. 
The mean age of women with stage 1 was 42.22, stage 2 was 51.00, stage 3 was 51.60 and 
stage 4 was 47.10 years. The mean age for women with stage 1 was a decade lower compared 
to other stages. Women with late stage disease were of low socio-economic status and low 
educational status. The demographic distribution of late stages of cervical cancer shows that 
there is an increase in late stage presentation in women above 50 years of age. 
The majority of women (41.75%) opted to discuss the problem with family members first after 
identifying symptoms that could be related to cervical cancer and hence delayed seeking 
healthcare assistance.  
The majority of women (86.41%) had consulted for healthcare in the 12 months prior to the 
study. Of these, 47.78% consulted at the public clinics/hospital and only 13.33% consulted at 
the GP and remainder consulted at traditional healers/faith healers etc. 
Squamous cell carcinoma is the commonest histological type and moderate differentiation 
being the commonest grading.  However, there is an increasing incidence of adeno-carcinoma with 
n=5 (8.0%) in stage 3 and n=2 (20%) in stage 4. 
There appears to be a consensus that the current screening method (cytology) and screening 
interval for cervical cancer are not effective for various reasons and may play a role in women 
presenting at late stage disease. Vaginal bleeding remain the commonest sign and probably a 
red flag for cervical cancer in post-menopausal women.  
46 
 
CHAPTER 7: REFERENCES  
1. Moodley J.  Cervical cancer in Southern Africa: The Challenges. South Afr J Gynaecol 
Oncol 2009; 1: 11-13 
2. South African Human Papillomavirus Advisory Board Cervical Cancer and Human 
Papillomavirus: Testing for Human Papillomavirus in the diagnosis and follow up of 
cervical neoplasia. 2010 
3. National Health Laboratory Services. Incidence of Histologically Diagnosed Cancer in 
South Africa, 1998-1999 National Cancer Registry. Published by the National Cancer 
Registry of South Africa, Johannesburg. December 2004. Available from: 
www.cansa.org.za/unique/cansa/files/stats98 Accessed 28th January 2012 
4. Parkin DM, Bray F, Ferlay J and Pisani P.  Global Cancer Statistics, 2002. CA Cancer J Clin 
2005; 55;74-108 
5. Scott JR, Gibbs RS, Karlan BY, Haney AF. Danforth’s Obstetrics and Gynaecology. 9th 
edition. Williams & Wilkins publishers; 2003 
6. Berek JS, Hacker NF. Practical Gynaecological Oncology. 3rd edition. Lippincott Williams 
& Wilkins Publishers; 2000 
7. South African Human Papillomavirus Advisory Board. Cervical Cancer and Human 
Papillomavirus: South African Guidelines for Screening and Testing. South Afr J 
Gynaecol Oncol. 2010; 2(1): 23-26 
8. South African Human Papillomavirus Advisory Board.  Prophylactic Human 
Papillomavirus (HPV) vaccination against cervical cancer. 2010 
9. Lim GCC.  Overview of Cancer in Malaysia. Jn J Clin Oncol 2002; 32 (Supplement): S37-
S42.doi: 10.1093/jjco/hye132. Available from: 
http://m.jjco.oxfordjournals.org/content/32/suppl_1/S37.full 
10. Devi BCR, Tang TS, Corbex M.  Reducing by half the percentage of late-stage 
presentation for breast and cervix cancer over 4 years: a pilot study of clinical down 
staging in Sarawak, Malaysia.  Annal Onc. 2002; 18 (7) : 1172-1176 
11. National Policy of the Department of Health for the Prevention of Cervical Cancer in  
South Africa: Draft One, September 22nd, 2011 
47 
 
12. Sheridan A, White J. U.K Department of Health.  Annual HPV Vaccine coverage in 
England. 2009/2010. Accessed 21 February 2012.  Available from: 
http://www.dh.gov.uk/en/ 
13. Australian Institute of Health and Welfare. Cervical Screening in Australia 2008-2009. 
The Australian Institute of Health and Welfare and the Australian Government 
Department of Health and Ageing for the National Cancer Screening Programme 
(October 2011): Cancer Series Number 61. Available from: 
www.aihw.gov.au/WorkArea/DownloadAsset. Accessed 12th January 2012 
14. De Kubber M, Peters A, Soeters R. Investigating Cervical Cancer Awareness: Perceptions 
of the female Cancer Programme in Mdantsane, South Africa. South Afr J Gynaecol 
Oncol 2011; 3(2): 70-72 
15. Jemal A, Brey F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA 
Cancer J Clin. 2011 March/April; 61(2) 69-90 
16. Greene FL; Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M.  AJCC Cancer 
Staging Handbook. 6th edition. New York: Springer; 2002 
17. Benedet JL, Pecorelli MD, Hacker NF. Staging classification and clinical practice 
guidelines of gynaecologic cancer. FIGO Committee on gynaecologic oncology. Elsevier; 
September 2000 
18. Shivnani AT, Rimel BJ, Schink J.  Cancer of the Cervix: Current Management and New 
Approaches: Oncology. 2006 November 1;  20(12) 
19. Sellors JW, Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial 
neoplasia: A beginners’ manual. IARC. Lyon; 2003 
20.  Berek JS. Norvask Gynaecology. 13th edition. Lippincott Williams & Wilkins Publishers; 
2002 
21. Snyman LC, Herbst U. Reasons why unscreened patients with cervical cancer present 
with advanced stage disease.  South Afr J Gynaecol Oncol 2013;5(1):16-20 
22. Cervical Cancer facts and figures. Public Health Agency of Canada. Accessed 18 January 
2012. Available from: www.phac-aspc-gc.ca/cd-mc/cancer/cervical_cancer_figures-
cancer_du_col_uterus-eng.php  
48 
 
23. Ndlovu N, Kambarami R. Factors associated with tumour stage at presentation in 
invasive cervical cancer. Cent Afr J Med. 2003 Sep-Oct; 49(9-10):107-11. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/15298465 
24. Anorlu RI, Orakwue CO, Oyeneyin L, Abudu OO. Late presentation of patients with 
cervical cancer to a tertiary hospital in Lagos: what is responsible? Eur J Gynaecol 
Oncol. 2004; 25(6):729-32. Available 
from:http://www.ncbi.nlm.nih.gov/pubmed/15597852 
25. Benedet J, Odicino F, Maisonneuve P, et al. Carcinoma of the Cervix Uteri: Annual report 
on the results of treatment in Gynaecologic Cancer. J Epidemiol Biostat 2001; 6:7-43. 
26. Were EO, Buziba NG. Presentation and health care seeking behaviour of patients with cervical 
cancer seen at Moi Teaching and Referral Hospital, Eldoret, Kenya. East Afr Med J. 2001 Feb; 
78(2):55-9. 
27. Smith T. Protocol for Treatment of Gynaecological Oncology. Department of Obstetrics and 
Gynaecology, Oncology Group. 10th edition University of the Witwatersrand; 2014 
28. Moodley M, Moodley J, Kleinschmidt I. (2001), Invasive cervical cancer and human 
immunodeficiency virus (HIV) infection: a South African perspective. Int J Gynecol Cancer, 
11: 194–197   
29. Adam Y, McIntire JA, De Bryn G. Incidence of cytological abnormalities within 24 months of a 
normal cervical smear in Soweto, South Africa. S Afr Med J. 2013; 103(1):34-39 
30. Durowade KA, Osagbemi GK, Salaudeen AG, Musa OI, Akande TM et al. Prevalence and risk 
factors of cervical cancer among women in an urban community of Kwara State, North Central 
Nigeria. J. Prev Med Hyg 2012; 53: 213-219 
31. Edgardh K. Sexual behaviour and early coitarche in a national sample of 17 year old 
Swedish girls Sex Transm Inf 2000;76:98–102 
 
 
 
 
 
 
49 
 
CHAPTER 8: APPENDICES  
 
8.1  Appendix A : Data Sheet 
PART A:  INFORMATION FROM THE FILE 
 
Stage at Presentation 
1 2 3 4 4 5 6 7 8 9 
1a 1b 2a 2b 3a 3b 4a 4b Other Unknown 
          
 
Histology 
Type 1 2 3 4 0 
 Squamous Adenocarcinoma Adeno-squamous Other    No report 
      
Grading 1 2 3 4 0 
 Well Moderate Poor Other No report 
      
 
Age (in years) 
   
 
HIV positive:  
1 0 Blank 
Yes No Not tested 
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Last CD4 Count 
Value   Unknown 
Date (Year/Month    
 
ARVs treatment 
1 0 Blank 
Yes No Not certain 
    
 
Period on ARVs (in months/years) 
Months    
Years    
 
Other tests/assessments on admission 
Test/Screen Results/values Pending 
Haemoglobin   
Weight   
WR/RPR   
U&E   
LFT   
Urine Cytology   
Sonar kidneys/ bladder/ liver   
Cystoscopy   
CXR   
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PART B:  INFORMATION FROM PATIENT INTERVIEW 
 
 Yes =1 No = 2 No answer =3 
 CIGARETTE SNUFF  
Have you ever used?    
Do you still use/smoke?     
If no, How long have you stopped (years)?    
How many times per day?    
How many cigarettes per day?    
Period of use all together    
 
Have you ever used contraceptives? 
Yes= 1 No= 0 Not answered= 3 Age when starting  
 Have you ever used  If yes, how long in years  (in years) 
C.O.C    
Depo Provera    
Nuristherone    
P.O.P    
I.U.C.D    
Condoms    
 
Are you the main provider at home? 
1 0 
Yes No 
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How much was your household income in past 5 years (in South African Rands) 
1 2 3 4 
Less than R1000 R1000-R2999 R3000-R4999 R5000 and above 
 
What is your highest level of education? 
 
How easy is it for you to access clinic or healthcare facility? 
 
Residential address 
 
 
Do you know what a Pap smear is?  
1 0 Dot 
Yes No Uncertain 
   
 
Have you had a Pap smear before the current diagnosis? 
1 2 Dot 
1 2 3 4 0 
Primary Secondary (no 
matric) 
Secondary (completed 
matric) 
Tertiary No formal 
education 
     
1 2 3 
Walking distance By taxi/vehicle(short trip) By taxi/vehicle(long trip) 
   
53 
 
Yes No Uncertain 
   
 
Previous Pap smear period (in months/years) 
Months      
Years      
 
Results of last Pap smear 
1 2 
Normal Abnormal 
  
 
 
If abnormal was it..?  
1 2 3 4 5 
LGSIL HGSIL Invasive Carcinoma Other (indicate) Don’t know results 
     
 
If the Pap smear was abnormal, was there further intervention done after the Pap smear 
results? 
1 2 3 4 
Colposcopy Colposcopy & LLETZ Punch Biopsy (No colposcopy) Uncertain 
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Now I am going to ask you very personal questions which may make you feel uncomfortable. 
You don’t have to answer if you do not feel like doing so.  
How old were you when you had sexual intercourse for the first time (in years) 
Age Not answered 
    
 
 
How many sexual partners in total have you had in your life? 
Number Not answered 
    
 
Have you had sexual transmitted diseases before? 
1 0 2 Dot 
Yes No Uncertain Not answered 
    
 
Please tell me how many times you have been pregnant and what was the outcome? 
 1 2 3 4 5 >5 Not answered 
Year        
Duration 
(months) 
       
Outcome        
 
 
I am now going to ask you questions about your medical symptoms at this admission.  
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What was it that alerted you to the fact there may be something wrong, that then brought you 
to the hospital?  
 
 
Did you have any of the following in the last 6 months? 
 1 2 3 4 5 6 
 Abnormal 
vaginal 
discharge  
Pain Abnormal 
bleeding  
Dyspareun
ia  
Weight 
loss  
Night 
sweats 
When did it 
start?(in months) 
      
mild       
moderate       
severe       
Is it improving?       
Is it getting worse?       
For how long has it 
been? 
      
What colour is the 
discharge 
      
Offensive 
discharge 
      
Non offensive 
discharge 
      
  
Pain Assessment Scale 
0 Mild 5  Moderate                Severe 10 
 
 
56 
 
What did you do after identifying the above-mentioned problem(s)? 
 
 
 
Have you been to a doctor/ health worker/ traditional health worker in the last year- if so what 
did you consult about? 
 
 
Where did you consult? 
 
Did you consider this problem major? 
1 0 2 Dot 
Yes No  Not certain Not answered 
    
 
 
PART C: OPEN-ENDED QUESTION 
 
I would like to now start my recorder before I ask you the next question 
A. You have been diagnosed with cancer, is that true? Cervical cancer is a slow growing 
cancer and takes a long time to develop and to show itself.... But I would like to ask you, 
when do you think the problem actually began?  
 
1 2 3 4 Dot 
Traditional healer Faith healers Alternative medicine  Other Not answered 
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Reply…………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………… 
 
 
 
B. Has anyone told you about cancer of the cervix and the tests used to check for it?  
 
Reply…………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………… 
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8.2  Appendix B : Patient Information 
 
 
My name is Dr.  Langanani Mbodi. I am a doctor in this hospital and I am training to become a 
specialist in Obstetrics and Gynaecology. As part of my training I am required to do a research 
project. I also work in theatre, labour ward, antenatal clinic and gynaecology department as 
part of my training. I have noticed that many patients with cancer of the cervix come to our 
hospital when the disease has spread and hence I am doing a study to find out some of the 
reasons for that and to identify ways of helping people with cancer to be diagnosed early and 
treated accordingly. 
 
I request you to take part in this study by giving me permission to obtain some of the 
information from your file as well as answer a few questions that I will ask you. I will also 
record some of your responses at the end. 
During the study there will be no examination done on you, no procedures such as taking 
blood and no new medication will be given to you. 
Please be informed that by taking part in the study you will not benefit directly, the standard 
of care you receive will be the same as other patient, your information and identity will remain 
confidential and your names will not be used on the data collection sheet. If at any point 
during or after the interview you no longer wish to continue you are welcome to withdraw and 
there will be on ill-effects. 
You can contact my supervisor Dr Y. Adam (Chris Hani Baragwanath Academic Hospital) or 
myself (telephone number 011 9338156) 
You can also contact the Human Research Ethics Committee on (011) 7171234 if you wish to 
get more information. 
If you are willing to take part in this study, kindly sign that you understood all that has been 
explained to you and that you are willing to take part in the study. 
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8.3  Appendix C : Patient Consent Form 
 
Consent form  
 
To be completed by participant or responsible person 
 
I voluntarily agree to participate in the research study described to me as per attached 
information form. I had some chance of asking questions about the research. 
 
 
__________________     _______________     ____________          ___________________ 
(Print name)       (Capacity)                      (Date)        (Signature) 
 
 
 
To be completed by the researcher/person obtaining consent 
 
I have discussed the proposed research with this patient or the responsible person, and in my 
opinion, this participant or responsible person understands what the research entails and is 
capable of freely consenting to participate in this research. 
 
 
__________________     _______________     ____________          ___________________ 
(Print name)       (Capacity)                      (Date)        (Signature) 
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8.4  Appendix D : Ethics Clearance 
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8.5 Appendix E : FIGO Staging of Cervical Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA1       Confined to the cervix, diagnosed only by microscopy with invasion of < 3 mm in depth 
and lateral spread < 7 mm 
 
IA2       Confined to the cervix, diagnosed with microscopy with invasion of > 3 mm and < 5 
mm with lateral spread < 7mm 
 
IB1       Clinically visible lesion or greater than A2, < 4 cm in greatest dimension 
 
IB2       Clinically visible lesion, > 4 cm in greatest dimension 
 
IIA1      Involvement of the upper two-thirds of the vagina, without parametrial invasion, < 4 
cm in greatest dimension 
 
IIA2      > 4 cm in greatest dimension 
 
IIB        With parametrial involvement 
 
IIIA Involvement of the lower third of the vagina. Sentence incomplete No extension to 
the pelvic sidewall but  
IIIB Extension into the pelvic sidewall or hydronephrosis or non-functioning kidney. 
 
IVA Spread of the tumor into adjacent pelvic organs.  
 
IVB Spread to distant organs. 
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8.6 Appendix F : Chris Hani Baragwanath Academic Hospital Permission 
 
